Thanks very much.
My apologies, as a member of the committee, for not having sufficient time to delve into these issues.
Let me say, Mr. Butler, that I appreciate the pitch you're making. I've spoken to producers in Nova Scotia and representatives in Newfoundland and Labrador. I absolutely hear what you're saying about the value of increasing access to markets, but I have also heard, from you and from those people, not at any price. Understand that, certainly from this side, we're thinking seriously about the points you've made.
Ms. Sullivan, we've talked before—and I think you understand where we're coming from and where we stand—and we certainly support the points you have made.
I'm going to move to the generics, and I want to say this to you: I was quite shaken by the study and the $2.8 billion increase in the cost of the health care system. I come from Nova Scotia, and the government there has worked closely with your sector and other sectors to try to get a handle on drug costs, and some considerable progress has been made.
Will you please tell me you've had some response from the Government of Canada about your study and about the potential impact of the increased patent protection on health care?